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Key Points

• Brief lenalidomide
consolidation after
chemoimmunotherapy
is acceptably tolerated
and extends PFS and
OS in CLL.
• FCR has superior efficacy compared with FR
chemoimmunotherapy
for CLL.

Prior to novel targeted agents for chronic lymphocytic leukemia (CLL), the best chemoimmunotherapy regimen in patients with non-del(11q) disease was unclear. The role of
lenalidomide was also not deﬁned. This phase 2 study randomized 342 untreated patients
with non-del(11q) CLL requiring therapy to ﬂudarabine plus rituximab (FR; n 5 123),
FR plus lenalidomide consolidation (FR1L; n 5 109), or FR plus cyclophosphamide
(FCR; n 5 110) and compared 2-year progression-free survival (PFS) rates of each to the
historical control rate with FC (60%). Patients with del(11q) in at least 20% of pretreatment
cells continued with FCR (n 5 27) or were reassigned to FCR1L (n 5 31) and excluded
from the primary analysis. Among non-del(11q) patients, 2-year PFS rates were 64%
(90% conﬁdence interval [CI], 57-71; FR), 72% (90% CI, 65-79; FR1L), and 74% (90% CI,
66-80; FCR); FR1L and FCR had rates signiﬁcantly greater than historical control.
Median PFS was signiﬁcantly shorter with FR compared with FR1L (P 5 .04) and FCR
(P , .001): 43 (95% CI, 33-50), 61 (95% CI, 45-71), and 97 (95% CI, 61 to not reached)
months, respectively. Median follow-up was 73 months and median overall survival (OS)
was only reached with FCR (101 months; 95% CI, 96 to not reached). With FR1L, the
risk of death decreased over time and was lower than with FR at later time points
(P 5 .01), but not signiﬁcantly different from FCR (P 5 .21). Future studies
incorporating short courses of lenalidomide into other novel treatment regimens
are justiﬁed.

Introduction
Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia. A plethora of prognostic
factors have been described that identify patients more likely to progress with symptoms. In many
cases, prognostic factors such as immunoglobulin heavy chain variable (IGHV) mutational status,1,2
ZAP-70 protein expression,3,4 recurrent somatic mutations,5 and cytogenetics6 tie to the biology of
CLL. CLL is treated upon development of symptoms or cytopenias, as there is no advantage with early
intervention.7 The evolution of CLL therapy has been dramatic with acceptance of fludarabinebased8-10 or fludarabine plus cyclophosphamide (FC)–based11 therapy given with rituximab (FCR).12
Submitted 18 December 2017; accepted 28 March 2018. DOI 10.1182/
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Phase 2 studies suggested that survival was prolonged with
fludarabine plus rituximab (FR) or FCR as compared with historical controls and indeed that a subset of patients receiving each
were disease-free at 10 years.13,14 Many years ago, this prompted
phase 3 studies in both relapsed and symptomatic, untreated
CLL with FCR compared with FC, which demonstrated significant
improvement with FCR in complete response (CR), progressionfree survival (PFS), and overall survival (OS).15 These mature
chemoimmunotherapy studies indicated that patients with del
(11q) may benefit from cyclophosphamide as part of their
chemoimmunotherapy.16 Further, retrospective studies demonstrated the adverse risk previously identified with del(11q) patients
receiving FR may be abrogated with the addition of cyclophosphamide.17 However, FCR is also associated with short-term
toxicity, including a 2% treatment-related mortality often from
infection, and also late onset therapy-related myeloid neoplasia.13,17
Thus, interest in the field at the time of this unreported, but
very mature study existed to (1) determine the feasibility of risk
stratification based upon interphase cytogenetic results in a
multicenter study; (2) determine whether traditional and novel
combination chemoimmunotherapy regimens might improve the
2-year PFS rate above the 60% reported in patients receiving
FC18 and thereby justify subsequent studies of 1 or more of
these; and (3) determine whether consolidation after chemoimmunotherapy was feasible and improved 2-year PFS rates. The
value of the primary end point of the study is now of minimal value
to the field, but of interest is the potential of short-term immunemodulation therapy after receipt of chemoimmunotherapy. Using
lenalidomide as this immune modulator and only administering
it for 6 months using a 21 days on/7 days off schedule, this trial
differs from all other maintenance studies performed with lenalidomide.
Despite the very modest value of the chemoimmunotherapy
question addressed in this trial given advances in CLL therapy, the
application of lenalidomide might be informative to the field.
Lenalidomide is one promising therapeutic agent active in CLL
and is approved for treatment of multiple myeloma, transfusiondependent anemia due to low- or intermediate-1-risk del 5q
myelodysplastic syndromes, and relapsed or refractory mantle
cell lymphoma. Lenalidomide promotes selective protein degradation through enhancing the activation of cereblon,19-21
resulting in depletion of IKZF1, IKZF3, and other target proteins that are important in these diseases. Despite promising
early studies of lenalidomide in CLL that demonstrated durable
responses, 22-24 its development has been challenging due
to toxicity and uncertainty about dose and schedule.24 One
particular toxicity is tumor flare, 25 which may be diminished
with cytoreduction prior to administering lenalidomide. 26,27 In
1 study examining low-dose lenalidomide as consolidation therapy
following pentostatin, cyclophosphamide, and rituximab (PCR),
lenalidomide improved response in ;25% of patients and time to
next treatment appeared to be improved when compared with
historical control with PCR alone.27
This Cancer and Leukemia Group B (CALGB) 10404 study is a
randomized phase 2 trial in untreated, symptomatic CLL
patients that addressed both the feasibility of genomic classification by interphase cytogenetics and also the value of different
chemoimmunotherapies (FR, FCR) and addition of brief lenalidomide
consolidation. CALGB is now a part of the Alliance for Clinical Trials in
Oncology.
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Patients and methods
Patients
This National Cancer Institute (NCI)–sponsored, North American
intergroup study (NCT00602459) led by Alliance/CALGB was
approved by the local site institutional review board (locations in the
supplemental Appendix). All patients provided written informed
consent. Patients enrolled on this study were 18 years of age and
older, had CLL with an absolute lymphocytosis of .5 3 109/L,
immunophenotype typical of CLL, and features defined by the
International Workshop on CLL (IWCLL) 2008 guidelines.28 All
patients had symptomatic intermediate (Rai29 1 or 2) or high risk
(Rai 3 or 4) stage CLL and a performance status of 2 or better.
Patients had no prior therapy for CLL and a creatinine #1.53 the
upper limit of normal. Patients were excluded if they required
chronic administration of corticosteroids for other medical conditions. Due to the unknown teratogenic potential of lenalidomide,
pregnant or nursing patients were not enrolled.

Treatment
Following enrollment, patients were assessed centrally for the
presence or absence of del(11q) by interphase cytogenetics.
Within strata defined by Rai stage at diagnosis, patients were then
randomized to 1 of 3 treatment regimens: arm A, FR; arm B, FR with
consolidative lenalidomide (FR1L); and arm C, FCR (Table 1).
Interphase cytogenetics available prior to cycle 2 of therapy were
then used to risk stratify patients. Patients without del(11q) in
$20% of cells remained in their randomized treatment arms,
whereas in view of better outcomes to FCR, patients with del(11q)
in $20% of cells initially randomized to arms A and B were
transitioned to arm D, where FCR was administered followed by
consolidative lenalidomide (FCR1L). Patients initially randomized to
arm C with FCR remained in that arm regardless of the del(11q)
result. Allopurinol 300 mg orally once daily was given for days 1 to
14 of treatment. TMP-sulfa and acyclovir (or equivalent) prophylaxis
was strongly recommended. Granulocyte colony-stimulating factors were allowed per American Society of Clinical Oncology
guidelines.30 Six cycles of induction therapy were planned. Patients
in all arms underwent response assessment ;10 months after
beginning induction therapy and patients in arms B and D who had
stable disease or better with an absolute neutrophil count of $1 3
109/L, platelets $100 3 109/L, and estimated glomerular filtration
rate $30 mL per minute proceeded to receive up to 6 lenalidomide
consolidation cycles (21 days every 28 days). Details regarding
dose modifications are outlined in the supplemental Methods.

Interphase cytogenetics
Stimulated fluorescent in situ hybridization (FISH) analyses were
performed on peripheral blood or bone marrow samples, as
previously described.31 FISH analyses probed for the chromosome
12 centromere, ATM (11q22.3), D13S319 (13q14.3), and TP53
(17p13.1) (Abbott Molecular Inc, Des Plaines, IL). For risk
stratification based upon del(11)(q22.3) positivity, patients were
required to have $20% of cells with loss of 1 copy.

Adverse event and response assessment
Adverse events were assessed by the NCI Common Terminology
Criteria for Adverse Events version 3.0 and was changed to 4.0 in
October 2010. As the regimens used in this trial have been widely
studied and published, only grade 3-5 adverse events are reported,
24 JULY 2018 x VOLUME 2, NUMBER 14

Table 1. Treatment in CALGB 10404
Time*
Month 1

Months 2-6

Arm A: FR
2

Arm B: FR1L
2

Arm C: FCR

Arm D: FCR1L

2

Fludarabine 25 mg/m IV days 1-5

Fludarabine 25 mg/m IV days 1-5

Fludarabine 25 mg/m IV days 1-3†

Rituximab 50 mg/m2 IVPB day 1

Rituximab 50 mg/m2 IVPB day 1

Cyclophosphamide 250 mg/m2 days 1-3†

Rituximab 325 mg/m2 IVPB day 3

Rituximab 325 mg/m2 IVPB day 3

Rituximab 50 mg/m2 IVPB day 1

Rituximab 375 mg/m2 IVPB day 5

Rituximab 375 mg/m2 IVPB day 5

Rituximab 325 mg/m2 IVPB day 2

2

Fludarabine 25 mg/m IV days 1-5
2

Rituximab 375 mg/m IVPB day 1

2

Fludarabine 25 mg/m IV days 1-5
2

Rituximab 375 mg/m IVPB day 1

Fludarabine 25 mg/m2 IV days 1-3†
2

Cyclophosphamide 250 mg/m days 1-3†
2

NA

Fludarabine 25 mg/m2 IV days 1-3†
Cyclophosphamide 250 mg/m2 days 1-3†

Rituximab 500 mg/m IVPB day 1

Rituximab 500 mg/m2 IVPB day 1

End of 9 mo

Full staging

Full staging

Full staging

Full staging

Month 10

NA

Lenalidomide 5 mg by mouth days 1-21

NA

Lenalidomide 5 mg by mouth days 1-21

Months 11-15

NA

Lenalidomide 10 mg by mouth days 1-21

NA

Lenalidomide 10 mg by mouth days 1-21

End of 18 mo

NA

Full staging

NA

Full staging

End of 24 mo

Full staging

Full staging

Full staging

Full staging

Patients with del(11q) disease initially randomized to arms A or B were reassigned to arm D after the first month.
IVPB, IV piggyback; NA, not applicable.
*Each cycle of therapy was 28 days.
†Patients 70 years of age and older received fludarabine 20 mg/m2 and cyclophosphamide 150 mg/m2.

regardless of attribution. For response assessment, this study used
the IWCLL 2008 response criteria which includes clinical, hematologic, and bone marrow features along with requirement of computed tomography scan examination.28 Evaluation of resolution of
splenomegaly was by physical examination. Responses were
assessed according to the schedule detailed in the supplemental
Methods, and results were reviewed and confirmed by the principal
investigator of this study (J.C.B.) in all cases.

Statistics
The primary objective of this randomized phase 2 study was to
compare the 2-year PFS rates for FR, FR1L, and FCR with
historical control data for FC18 in non-del(11q) patients. With a
targeted 103 patients per arm with non-del(11q), there was at least
84% power to detect an improvement in 2-year PFS rate from 60%
to 73%, using a critical value of 69% and constraining the onesided type I error rate to 4%. Two-year PFS rate was defined
as the percentage of evaluable patients who were alive and
progression-free at 2 years. Patients who were lost to follow-up,
received a nonprotocol CLL therapy, or had a documented
progression or death prior to 2 years were considered treatment
failures. Transplant prior to progression was only documented in
4 patients, and thus was not accounted for when calculating the
PFS rate. Two-year PFS rates and their exact 90% confidence
intervals (CIs) are reported within each arm separately as the
primary analysis.
Secondary end points included time-to-event PFS and OS, overall
response rate (ORR), and CR rate. PFS was defined as time from
randomization until the first date of progression or death from any
cause, censoring patients alive and progression-free at the date of
last clinical assessment. Patients who received nonprotocol CLL
therapy (other than transplant) prior to a documented progression
were censored at the start date of the subsequent therapy. OS was
defined as time from randomization until the date of death from any
cause, censoring those alive at the date of last contact. Overall
response was defined as complete or partial remission. Logistic
24 JULY 2018 x VOLUME 2, NUMBER 14

regression and proportional hazard models were used to assess the
impact of baseline characteristics of patients with non-del(11q) on
response and PFS/OS, respectively.32,33
Detailed analysis methods for secondary comparisons are located
in the supplemental Methods. All reported P values are 2-sided. All
data were collected by the Alliance Statistics and Data Center
(SDC) and analyses were performed by the Alliance SDC
using SAS version 9.4. Data were locked for this analysis as of
23 August 2017.

Results
Enrollment, feasibility of treatment assignment, and
patient characteristics
A total of 418 patients enrolled on this study between March
2008 and August 2012. As depicted in the CONSORT diagram
(Figure 1), 400 patients are included in this analysis. Of the
18 patients not included, 7 never started treatment, 2 were ineligible,
1 withdrew consent for use of all data, and 8 with del(11q) had no
reassignment to arm D (they were assigned to arm A or B prior to an
amendment adding arm D). In addition, 15 patients did not have
interphase cytogenetics results; a sample was not received by the
central laboratory in 12, and a FISH result was not obtained in 3.
These patients were included in the analysis within the arms to which
they were initially randomized. Thus, central assignment of treatment
by interphase cytogenetics by the second cycle of therapy was
feasible in 385 patients (96%).
Baseline characteristics of the 400 patients are presented by
treatment arm and by del(11q) status. Characteristics for 342
non-del(11q) patients were similar across treatment arms except
for a higher frequency of hepatomegaly among the FCR treated
patients (Table 2). Characteristics for 58 del(11q) patients
were also similar between treatment arms (Table 3). Patients
with del(11q) have similar characteristics as those without this
abnormality, with exception of bulky (.5 cm) lymph nodes
(supplemental Table 1).
LENALIDOMIDE CONSOLIDATION IMPROVES OUTCOME IN CLL
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Randomize
N=418

Arm A Cycle 1
N=138

Arm B Cycle 1
N=140

Arm C Cycles 1-6
N=140

Excluded N=5
3 cancelled
2 with del(11q) and no
reassignment to Arm D

Excluded N=10
2 cancelled
1 ineligible
1 withdrew consent
6 with del(11q) and no
reassignment to Arm D

Excluded N=3
2 cancelled
1 ineligible

Arm A Cycles 2-6
Non-del(11q)
N=123

Arm A, del(11q)
Re-assigned to Arm D
N=10

Arm B Cycles 2-6
Non-del(11q)
N=109

Received Lenalidomide
Consolidation
N=69

Arm B, del(11q)
Re-assigned to Arm D
N=21

Arm C Cycles 2-6
Non-del(11q)
N=110

Arm C Cycles 2-6
del(11q)
N=27

Did Not Receive
Lenalidomide
Consolidation
N=40

Arm D Cycles 2-6
del(11q)
N=31

Received Lenalidomide
Consolidation
N=18

Did Not Receive
Lenalidomide
Consolidation
N=13

Figure 1. CONSORT diagram. Arm A 5 FR. Arm B 5 FR1L. Arm C 5 FCR. Arm D 5 FCR1L.

Tolerability and adverse events
The majority of patients received all 6 cycles of induction therapy
(non-del(11q): FR, 71%; FR1L, 66%; FCR, 61%; del(11q):
FCR, 30%, FCR1L, 65%), although fewer patients received
all assigned induction therapy in the 2 FCR-treated groups.
Among patients who received lenalidomide consolidation, most
patients received all 6 planned cycles (non-del(11q): FR1L, 78%;
del(11q): FCR1L, 61%). Among those who did not receive all
6 cycles, most have off-treatment reason as adverse event (60%
for FR1L and 57% for FCR1L). Specific details related to
treatment administration are in supplemental Table 2. Failure
to complete therapy in each of the groups was most commonly
due to failure to recover blood counts, toxicity of therapy, or
progression on therapy.
Six fatal events occurred during induction therapy: 3 with FR and
3 with FCR. These include a case of John Cunningham (JC) virus
encephalopathy (non-del(11q) with FR), autoimmune hemolytic
anemia following cycle 2 of FR (non-del(11q) with FR1L), death
related to disease progression (non-del(11q) with FR1L), pneumonitis (non-del(11q) with FCR), sepsis (non-del(11q) with FCR),
and sepsis/diarrhea (del(11q) with FCR). There were no grade
5 events with lenalidomide consolidation.
Grade 3 or greater adverse events occurring in at least 5% of
patients are summarized by treatment arm and by del(11q) status in
Table 4. Summaries of all reported grade 3 or greater adverse
events and new primary or new secondary malignancies are
provided in supplemental Tables 4 and 5. In general, adverse
1708
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events were manageable and typical of those reported with these
different chemoimmunotherapy regimens or monotherapy with
lenalidomide.

Outcome of therapy
The primary objective of this study was to determine whether PFS
rate at 2 years for non-del(11q) patients treated in each of 3
experimental arms (arm A, FR; arm B, FR1L; and arm C, FCR) was
sufficiently improved relative to historical control with FC to warrant
further study. Non-del(11q) patients treated with FR had a 2-year
PFS rate of 64% (90% CI, 57-71), whereas those in the FR1L
and FCR groups had higher 2-year PFS rates of 72% (90% CI,
65-79) and 74% (90% CI, 66-80), respectively. Only the
FR1L and FCR groups had 2-year PFS rates significantly higher
than the 60% previously reported with FC18 to be considered for a
future phase 3 trial (P 5 .008 and P 5 .004, respectively). Table 5
summarizes 2-year PFS rates with exact 90% CIs by treatment arm
and del(11q) status.
Secondary end points of the study included best ORR, CR rate, and
time-to-event PFS and OS. The best ORR occurring with therapy
did not differ significantly across the groups (non-del(11q): FR,
75%; FR1L, 69%; FCR, 71%; del(11q): FCR, 59%, FCR1L,
74%), although CR rates did (non-del(11q): FR, 32%; FR1L, 32%;
FCR, 51%; del(11q): FCR, 19%, FCR1L, 35%). For non-del(11q)
patients, those with FCR treatment had a significantly higher CR
rate than those with FR and FR1L treatment (P , .01 for each).
A summary of response rates with 90% CIs is shown by treatment
arm and del(11q) status in supplemental Table 5.
24 JULY 2018 x VOLUME 2, NUMBER 14

Table 2. Baseline characteristics of patients evaluated on the non-del(11q) treatment arms
Variable

FR, N 5 123

Median age (range), y

61 (28-81)

FR1L, N 5 109
62 (36-79)

FCR, N 5 110
60 (32-80)

P*
.97
.76

Sex, n (%)
Male

83 (67)

69 (63)

70 (64)

Female

40 (33)

40 (37)

40 (36)

26 (21)

23 (21)

23 (21)

.98

Rai stage, no. (%)
I
II

40 (33)

31 (28)

37 (34)

III

25 (20)

22 (20)

21 (19)

IV

32 (26)

33 (30)

29 (26)

0

61 (50)

60 (55)

60 (55)

1

58 (47)

44 (40)

47 (43)

.81

ECOG PS, no. (%)

2

4 (3)

5 (5)

3 (3)

Median hemoglobin (range), g/L

128 (59-161)

120 (59-162)

119 (69-173)

.18

Median platelets (range), 3109/L

151 (48-486)

133 (24-410)

133 (12-303)

.46

Median WBC (range), 3109/L

72.9 (2.2-424.9)

92.6 (6.2-476.9)

80.8 (1.2-899.8)

No

22 (18)

16 (15)

17 (16)

Yes

97 (82)

89 (85)

87 (84)

No

57 (46)

64 (59)

48 (44)

Yes

66 (54)

45 (41)

60 (56)

No

109 (90)

100 (92)

95 (86)

Yes

12 (10)

9 (8)

15 (14)

No

71 (60)

56 (52)

55 (51)

Yes

48 (40)

52 (48)

52 (49)

.07

LDH above normal, no. (%)

.44

Serum creatinine above normal, no. (%)

.37

Palpable splenomegaly, no. (%)

.005

Palpable hepatomegaly, no. (%)
No

116 (98)

98 (94)

93 (88)

Yes

2 (2)

6 (6)

13 (12)

4 (3)

2 (2)

3 (3)

Yes, lymph node ,5cm

80 (70)

74 (72)

80 (74)

Yes, lymph node 5-10cm

24 (21)

23 (22)

15 (14)

Yes, lymph node .10cm

7 (6)

4 (4)

10 (9)

Absent

106 (89)

92 (91)

96 (90)

Present

13 (11)

9 (9)

11 (10)

Absent

111 (93)

94 (93)

101 (94)

Present

8 (7)

7 (7)

6 (6)

Absent

90 (76)

79 (78)

74 (69)

Present

29 (24)

22 (22)

33 (31)

.50

Adenopathy, no. (%)
No adenopathy

.52
.79

B2M above normal, no. (%)

.90

del(17p), no. (%)

.92

del(11q),† no. (%)

.30

Trisomy 12, no. (%)

Percent values are calculated out of the number of patients with nonmissing data in each category.
B2M, b-2 microglobulin; ECOG PS indicates Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase; WBC, white blood cell count.
*x2 or Fisher’s exact and Kruskal-Wallis P values are presented for categoric and continuous variables, respectively.
†The del(11q) category includes patients with del(11q) detected in .2.3% of cells (above background) and in ,20% of cells.
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Table 2. (continued)
Variable

FR, N 5 123

FR1L, N 5 109

FCR, N 5 110

.14

del(13q), no. (%)
Absent

60 (50)

39 (39)

54 (50)

Present

59 (50)

62 (61)

53 (50)

13 (11)

9 (9)

11 (10)

.56

Hierarchical cytogenetic classification, no. (%)
del(17p)
del(11q)

P*

7 (6)

6 (6)

4 (4)

Trisomy 12

25 (21)

20 (20)

31 (29)

None

23 (19)

19 (19)

26 (24)

del(13q)

51 (43)

47 (47)

35 (33)

Percent values are calculated out of the number of patients with nonmissing data in each category.
B2M, b-2 microglobulin; ECOG PS indicates Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydrogenase; WBC, white blood cell count.
*x2 or Fisher’s exact and Kruskal-Wallis P values are presented for categoric and continuous variables, respectively.
†The del(11q) category includes patients with del(11q) detected in .2.3% of cells (above background) and in ,20% of cells.

Impact of lenalidomide
Among the 69 non-del(11q) patients who received lenalidomide
consolidation as part of the FR1L group, 3 of 31 patients who had a
partial response (PR) with induction therapy converted to CR with
time and continued therapy. Among the 18 del(11q) patients who
received lenalidomide consolidation as part of the FCR1L group,
2 of 10 patients who had a PR with induction therapy converted to
CR with time and continued therapy.
Despite the absence of marked response improvement with
lenalidomide, the 2-year PFS rates nonetheless suggest clinical
benefit with lenalidomide consolidation following FR in non-del(11q)
patients. Furthermore, time-to-event PFS was significantly improved
in the non-del(11q) patients in the FR1L group vs the non-del(11q)
patients who received FR alone (P 5 .04; Figure 2A). The median
PFS was 60.7 months (95% CI, 44.8-71.3) with FR1L vs 43.5
months (95% CI, 32.8-50.2) with FR. In non-del(11q) patients
receiving FCR, the median PFS was 97.2 months (95% CI, 61.4 to
not reached) and significantly longer from those treated with FR
alone (P , .001; Figure 2A). Even though the median PFS was
longer with FCR than with FR1L, the difference in PFS did not
reach statistical significance (P 5 .07).
For del(11q) patients treated with FCR, median PFS was 35.5 months
(95% CI, 21.8-65.5), significantly shorter than that observed in
non-del(11q) patients receiving FCR (P 5 .006). Thus, the data fail
to support the hypothesis that the inclusion of cyclophosphamide
abrogates the poor outcome associated with del(11q). In del(11q)
patients treated with FCR1L, the median PFS was 41.2 months
(95% CI, 25.7-50.7). Even though this was longer than the median
PFS with FCR alone in del(11q) patients, the curves for the 2 groups
overlapped (P 5 .98; Figure 2B).

Overall survival
OS was estimated according to treatment arm and del(11q) status
(Figure 2C-D). With a median follow-up of 73 months (range, 2-112
months), the median OS has only been reached in the group of nondel(11q) patients receiving FCR (median 5 101.1 months; 95% CI,
95.6 to not reached). Among the non-del(11q) patients, OS was
not significantly different between the FR1L and FR/FCR treatment
groups (P 5 .20 and P 5 .26, respectively; Figure 2C). However, in
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the FR1L treatment group, there have been only 5 deaths beyond
48 months in 89 at-risk patients compared with 21 and 12 deaths
beyond 48 months among 108 and 90 at-risk patients in the FR
and FCR groups, respectively.

Univariable and multivariable analyses of outcome
Secondary objectives of this study included evaluating baseline
features associated with end points of clinical benefit, such as ORR,
PFS, and OS among the non-del(11q) patients.
For ORR, interphase cytogenetics was significantly associated with
outcome when adjusting for other variables (supplemental Table 6).
Using the Dohner hierarchical classification for cytogenetics,6 patients
with del(17p) had lower odds of responding compared with patients with the low-risk classification of del(13q); only 11 of 30 patients
(37%) with del(17p) responded to therapy, all with partial responses,
as opposed to 79 of 112 patients (71%) with del(13q). There were no
significant differences in the odds of response according to treatment
group (P . .20 for all pairwise comparisons).
For PFS, higher WBC count, bulky nodes, interphase cytogenetics
and treatment group were significant in the multivariable analysis (supplemental Table 7). Both interphase cytogenetics and treatment group violated the assumption of proportional hazards (P , .01),
and therefore the hazard ratio (HR) was allowed to change over
time in the model. The risk of an event was significantly higher
for patients classified with del(17p) and those classified with del
(11q) in ,20% of cells compared with those classified with del
(13q). The risk of an event for patients with del(17p) was highest
at early time points in the study, with an HR of 2.39 (95% CI,
1.24-4.61) at year 2 and an HR of 1.29 (95% CI, 0.48-3.50) for
those still at risk at year 5. Conversely, the risk of an event for
patients with low levels of del(11q) increased over time, with an
HR of 2.85 (95% CI, 1.39-5.82) at year 2 and an HR of 8.26
(95% CI, 2.60, 26.27) for those still at risk at year 5. For patients
who were in treatment groups FR1L and FCR, the risk of an event
was increasingly lower than for patients who received FR; at year 5,
the HR was 0.43 (95% CI, 0.24-0.79) and 0.21 (95% CI, 0.11-0.41),
respectively, relative to the FR treatment group. There was no
significant difference in PFS between the FR1L and FCR treatment
groups (P 5 .12).
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Table 3. Baseline characteristics of patients with del(11q) disease
Variable

FCR, N 5 27

Median age (range), y

60 (41-78)

FCR1L, N 5 31
59 (30-75)

P*
.50
.27

Sex, no. (%)
Male

16 (59)

23 (74)

Female

11 (41)

8 (26)

I

4 (15)

8 (26)

II

8 (30)

14 (45)

III

6 (22)

4 (13)

IV

9 (33)

5 (16)

0

16 (59)

17 (55)

1

10 (37)

13 (42)

.25

Rai stage, no. (%)

.89

ECOG PS, no. (%)

2

1 (4)

1 (3)

Median hemoglobin (range), g/L

121 (70-154)

120 (35-151)

.83

Median platelets (range), 3109/L

125 (37-275)

159 (44-375)

.34

Median WBC (range), 3109/L

69.1 (10.6-289.0)

77.1 (6.3-244.9)

.86
.51

B2M above normal, no. (%)
No

7 (29)

5 (18)

Yes

17 (71)

23 (82)

No

15 (58)

14 (48)

Yes

11 (42)

15 (52)

No

25 (96)

28 (93)

Yes

1 (4)

2 (7)

No

14 (52)

18 (58)

Yes

13 (48)

13 (42)

.59

LDH above normal, no. (%)

1.00

Serum creatinine above normal, no. (%)

.79

Palpable splenomegaly, no. (%)

.36

Palpable hepatomegaly, no. (%)
No

26 (96)

26 (87)

Yes

1 (4)

4 (13)

0 (0)

0 (0)

Yes, lymph node ,5 cm

12 (50)

15 (52)

Yes, lymph node 5-10 cm

10 (42)

12 (41)

Yes, lymph node .10 cm

2 (8)

2 (7)

Absent

26 (96)

29 (94)

Present

1 (4)

2 (6)

Absent

23 (85)

25 (81)

Present

4 (15)

6 (19)

Absent

13 (48)

9 (29)

Present

14 (52)

22 (71)

1.00

Adenopathy, no. (%)
No adenopathy

1.00

del(17p), no. (%)

.74

Trisomy 12, no. (%)

.18

del(13q), no. (%)

Percent values are calculated out of the number of patients with nonmissing data in each category.
Abbreviations are explained in Table 2.
*Fisher’s exact and Kruskal-Wallis P values are presented for categoric and continuous variables, respectively.
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Table 4. Grade 3-5 adverse events occurring in at least 5% of patients
Adverse event type

Arm/group

Grade 3, no. (%)

Grade 4, no. (%)

Grade 5, no. (%)

Hematologic
Hemoglobin

Hemolysis

Leukocytes (total WBC)

A: FR, non-del(11q)

15 (13)

3 (3)

0 (0)

B: FR1L, non-del(11q)

12 (11)

4 (4)

0 (0)

C: FCR, non-del(11q)

22 (21)

4 (4)

0 (0)

C: FCR, del(11q)

4 (15)

0 (0)

0 (0)

D: FCR1L, del(11q)

2 (6)

2 (6)

0 (0)

A: FR, non-del(11q)

1 (1)

0 (0)

0 (0)

B: FR1L, non-del(11q)

3 (3)

0 (0)

1 (1)

C: FCR, non-del(11q)

0 (0)

0 (0)

0 (0)

C: FCR, del(11q)

0 (0)

0 (0)

0 (0)

D: FCR1L, del(11q)

2 (6)

1 (3)

0 (0)

A: FR, non-del(11q)

29 (25)

7 (6)

0 (0)

B: FR1L, non-del(11q)

22 (20)

12 (11)

0 (0)

C: FCR, non-del(11q)

22 (21)

11 (10)

0 (0)

6 (23)

3 (12)

0 (0)

3 (10)

0 (0)

C: FCR, del(11q)

Lymphopenia

Neutrophils/granulocytes (ANC/AGC)

Platelets

D: FCR1L, del(11q)

6 (19)

A: FR, non-del(11q)

25 (21)

11 (9)

0 (0)

B: FR1L, non-del(11q)

19 (18)

13 (12)

0 (0)

C: FCR, non-del(11q)

23 (22)

18 (17)

0 (0)

C: FCR, del(11q)

2 (8)

6 (23)

0 (0)

D: FCR1L, del(11q)

5 (16)

4 (13)

0 (0)

A: FR, non-del(11q)

43 (37)

33 (28)

0 (0)

B: FR1L, non-del(11q)

35 (32)

42 (39)

0 (0)

C: FCR, non-del(11q)

30 (28)

44 (42)

0 (0)

C: FCR, del(11q)

9 (35)

13 (50)

0 (0)

D: FCR1L, del(11q)

8 (26)

14 (45)

0 (0)

A: FR, non-del(11q)

9 (8)

1 (1)

0 (0)

B: FR1L, non-del(11q)

9 (8)

4 (4)

0 (0)

C: FCR, non-del(11q)

15 (14)

7 (7)

0 (0)

C: FCR, del(11q)

3 (12)

1 (4)

0 (0)

D: FCR1L, del(11q)

3 (10)

1 (3)

0 (0)

A: FR, non-del(11q)

0 (0)

0 (0)

0 (0)

B: FR1L, non-del(11q)

1 (1)

0 (0)

0 (0)

C: FCR, non-del(11q)

6 (6)

0 (0)

0 (0)

C: FCR, del(11q)

0 (0)

0 (0)

0 (0)

D: FCR1L, del(11q)

0 (0)

0 (0)

0 (0)

A: FR, non-del(11q)

4 (3)

0 (0)

0 (0)

B: FR1L, non-del(11q)

15 (14)

1 (1)

0 (0)

C: FCR, non-del(11q)

11 (10)

1 (1)

0 (0)

C: FCR, del(11q)

0 (0)

0 (0)

0 (0)

D: FCR1L, del(11q)

0 (0)

0 (0)

0 (0)

Nonhematologic
Hypertension

Fatigue

Rash (desquamation)

A: FR, non-del(11q)

6 (5)

0 (0)

0 (0)

B: FR1L, non-del(11q)

4 (4)

1 (1)

0 (0)

C: FCR, non-del(11q)

7 (7)

0 (0)

0 (0)

C: FCR, del(11q)

0 (0)

0 (0)

0 (0)

D: FCR1L, del(11q)

2 (6)

0 (0)

0 (0)

Percent values are calculated out of the number of patients who started treatment and submitted at least 1 adverse event form for each group: FR in non-del(11q) (n 5 117), FR 1 L in nondel(11q) (n 5 109), FCR in non-del(11q) (n 5 106), FCR in del(11q) (n 5 26), FCR 1 L in del(11q) (n 5 31).
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Table 4. (continued)
Adverse event type

Arm/group

Diarrhea

Febrile neutropenia

Infection with ANC grade ,3

Infection with ANC grade $3

ALT, SGPT

Glucose, serum-high (hyperglycemia)

Phosphate, serum-low (hypophosphatemia)

Potassium, serum-low (hypokalemia)

Sodium, serum-low (hyponatremia)

Treatment-related secondary malignancy

Grade 3, no. (%)

Grade 4, no. (%)

Grade 5, no. (%)

A: FR, non-del(11q)

2 (2)

0 (0)

0 (0)

B: FR1L, non-del(11q)

5 (5)

0 (0)

0 (0)

C: FCR, non-del(11q)

2 (2)

0 (0)

0 (0)

C: FCR, del(11q)

0 (0)

0 (0)

0 (0)

D: FCR1L, del(11q)

0 (0)

0 (0)

0 (0)

A: FR, non-del(11q)

14 (12)

1 (1)

0 (0)

B: FR1L, non-del(11q)

16 (15)

1 (1)

0 (0)

C: FCR, non-del(11q)

17 (16)

2 (2)

0 (0)

C: FCR, del(11q)

3 (12)

0 (0)

0 (0)

D: FCR1L, del(11q)

5 (16)

0 (0)

0 (0)

A: FR, non-del(11q)

4 (3)

0 (0)

0 (0)

B: FR1L, non-del(11q)

5 (5)

1 (1)

0 (0)

C: FCR, non-del(11q)

4 (4)

0 (0)

0 (0)

C: FCR, del(11q)

0 (0)

0 (0)

0 (0)

D: FCR1L, del(11q)

0 (0)

0 (0)

0 (0)

A: FR, non-del(11q)

5 (4)

0 (0)

0 (0)

B: FR1L, non-del(11q)

12 (11)

0 (0)

0 (0)

C: FCR, non-del(11q)

7 (7)

0 (0)

0 (0)

C: FCR, del(11q)

0 (0)

0 (0)

0 (0)

D: FCR1L, del(11q)

0 (0)

0 (0)

0 (0)

A: FR, non-del(11q)

4 (3)

0 (0)

0 (0)

B: FR1L, non-del(11q)

6 (6)

1 (1)

0 (0)

C: FCR, non-del(11q)

2 (2)

1 (1)

0 (0)

C: FCR, del(11q)

0 (0)

0 (0)

0 (0)

D: FCR1L, del(11q)

0 (0)

1 (3)

0 (0)

A: FR, non-del(11q)

3 (3)

0 (0)

0 (0)

B: FR1L, non-del(11q)

8 (7)

2 (2)

0 (0)

C: FCR, non-del(11q)

11 (10)

3 (3)

0 (0)

C: FCR, del(11q)

0 (0)

0 (0)

0 (0)

D: FCR1L, del(11q)

1 (3)

0 (0)

0 (0)

A: FR, non-del(11q)

1 (1)

0 (0)

0 (0)

B: FR1L, non-del(11q)

6 (6)

0 (0)

0 (0)

C: FCR, non-del(11q)

1 (1)

0 (0)

0 (0)

C: FCR, del(11q)

1 (4)

0 (0)

0 (0)

D: FCR1L, del(11q)

1 (3)

0 (0)

0 (0)

A: FR, non-del(11q)

2 (2)

0 (0)

0 (0)

B: FR1L, non-del(11q)

2 (2)

0 (0)

0 (0)

C: FCR, non-del(11q)

1 (1)

0 (0)

0 (0)

C: FCR, del(11q)

0 (0)

0 (0)

0 (0)

D: FCR1L, del(11q)

2 (6)

0 (0)

0 (0)

A: FR, non-del(11q)

3 (3)

0 (0)

0 (0)

B: FR1L, non-del(11q)

4 (4)

0 (0)

0 (0)

C: FCR, non-del(11q)

5 (5)

0 (0)

0 (0)

C: FCR, del(11q)

2 (8)

0 (0)

0 (0)

D: FCR1L, del(11q)

0 (0)

0 (0)

0 (0)

A: FR, non-del(11q)

0 (0)

2 (2)

0 (0)

B: FR1L, non-del(11q)

1 (1)

0 (0)

0 (0)

Percent values are calculated out of the number of patients who started treatment and submitted at least 1 adverse event form for each group: FR in non-del(11q) (n 5 117), FR 1 L in nondel(11q) (n 5 109), FCR in non-del(11q) (n 5 106), FCR in del(11q) (n 5 26), FCR 1 L in del(11q) (n 5 31).
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Table 4. (continued)
Adverse event type

Pain

Dsypnea

Hypoxia

Arm/group

Grade 3, no. (%)

Grade 4, no. (%)

Grade 5, no. (%)

C: FCR, non-del(11q)

2 (2)

2 (2)

0 (0)

C: FCR, del(11q)

0 (0)

0 (0)

0 (0)

D: FCR1L, del(11q)

2 (6)

1 (3)

0 (0)

A: FR, non-del(11q)

8 (7)

0 (0)

0 (0)

B: FR1L, non-del(11q)

12 (11)

0 (0)

0 (0)

C: FCR, non-del(11q)

13 (12)

0 (0)

0 (0)

C: FCR, del(11q)

2 (8)

0 (0)

0 (0)

D: FCR1L, del(11q)

0 (0)

0 (0)

0 (0)

A: FR, non-del(11q)

3 (3)

0 (0)

0 (0)

B: FR1L, non-del(11q)

4 (4)

2 (2)

0 (0)

C: FCR, non-del(11q)

3 (3)

2 (2)

0 (0)

C: FCR, del(11q)

2 (8)

0 (0)

0 (0)

D: FCR1L, del(11q)

0 (0)

0 (0)

0 (0)

A: FR, non-del(11q)

0 (0)

0 (0)

0 (0)

B: FR1L, non-del(11q)

2 (2)

0 (0)

0 (0)

C: FCR, non-del(11q)

0 (0)

1 (1)

0 (0)

C: FCR, del(11q)

0 (0)

0 (0)

0 (0)

D: FCR1L, del(11q)

2 (6)

0 (0)

0 (0)

Percent values are calculated out of the number of patients who started treatment and submitted at least 1 adverse event form for each group: FR in non-del(11q) (n 5 117), FR 1 L in nondel(11q) (n 5 109), FCR in non-del(11q) (n 5 106), FCR in del(11q) (n 5 26), FCR 1 L in del(11q) (n 5 31).

For OS, age $65 years, interphase cytogenetics and treatment
group were significant in the multivariable analysis (supplemental
Table 8). Specifically, the risk of death was significantly higher for
patients classified with del(17p) compared with those classified
with del(13q) (P 5 .0002). With respect to treatment group, the
proportional hazards assumption was violated (P 5 .04) and the HR
was allowed to change over time in the model. Accounting for
nonproportional hazards, the risk of death for patients in treatment
group FR1L decreased over time and was significantly lower than
the risk of death for patients in treatment group FR at later time
points (P 5 .01). The risk of death for those in the FCR treatment
group was not significantly different from those in the FR or FR1L
groups (P 5 .12 and P 5 .21, respectively).
A post hoc exploratory data analysis was conducted in the
subgroup of patients aged 65 years or older because these
patients have historically been underrepresented in clinical trials.
Among the 400 patients analyzed, 144 (36%) were at least
65 years old. In this subgroup of patients, the CR rate was 38%
(95% CI, 30-46) and the ORR was 66% (95% CI, 58-74).
The median PFS was 55 months (95% CI, 45-66) and the median
OS was 96 months (95% CI, 76 to not reached). Large differences
in response rates, PFS, and OS were not observed according to
treatment arm in this subgroup of patients (supplemental Table 9).

treatment strategies exceeded the 2-year PFS rate observed with
FC in earlier studies.19 FR was not as effective as measured by PFS,
being more similar to reported outcomes for FC.20,34 Adverse
events with each induction therapy were manageable and the
majority of non-del(11q) patients received all 6 cycles. Additionally,
this trial demonstrated in a randomized phase 2 trial the benefit
of short-term lenalidomide therapy as consolidation treatment.
Collectively, these findings provide further justification together
with other reported phase 3 trials performed with consolidative
lenalidomide35,36 to justify its use in future clinical trials.
This trial successfully used for the first time centrally assessed
interphase cytogenetics to risk stratify patients in a multicenter
study based upon the presence of del(11q). Despite earlier data
suggesting that FCR might abrogate the poor outcome associated
with this aberration,17 in our cohort, patients with del(11q) had a
considerably shorter PFS compared with non-del(11q) patients
who received FCR. In addition, the CR rate with FCR in patients
Table 5. PFS rates at 2 y
Arm/group

N

No. of successes*

%

Exact 90% CI, %

A: FR, non-del(11q)

123

79

64

57-71

B: FR 1 L, non-del(11q)

109

79

72

65-79

Discussion

C: FCR, non-del(11q)

110

81

74

66-80

This large randomized phase 2 study has identified 2 treatment
strategies that could be pursued in future phase 3 trials for
previously untreated non-del(11q) CLL patients requiring therapy,
including chemoimmunotherapy with either FR1L or FCR. Both

C: FCR, del(11q)

27

15

56

38-72

D: FCR 1 L, del(11q)

31

20

65

48-79
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*Patients lost to follow-up, starting nonprotocol therapy, or with progressions or deaths
prior to 2 years were treated as failures.
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Figure 2. PFS and OS. (A) PFS for patients with non-del(11q) disease and assigned to FR, FR1L, or FCR. (B) PFS for patients with del(11q) disease and assigned to FCR
or reassigned to FCR1L. (C) OS for patients with non-del(11q) disease and assigned FR, FR1L, or FCR. (D) OS for patients with del(11q) disease and assigned to FCR or
reassigned to FCR1L.

A novel observation of our study is that lenalidomide consolidation
for 6 cycles after FR, despite producing no measurable improvement in response rate, significantly impacted both PFS and OS
when compared with chemoimmunotherapy with FR alone. In a
multivariable analysis for OS, the risk of death for those in the FR1L
group decreased over time and was lower relative to those receiving
FR at later time points (P 5 .01) Collectively, this provides
increased interest in investigating lenalidomide or similar therapeutic agents as consolidation therapy for CLL.

An earlier study examining lenalidomide consolidation after completion of pentostatin, cyclophosphamide, and rituximab (PCR) demonstrated improved time to next treatment over previous PCR
outcomes.38 In this PCR1L trial, the authors demonstrated improved
T-cell function in vivo, similar to previous reports with this agent.38,39
Thus, an immunologic anti-tumor response to lenalidomide could
explain our observation. In addition, lenalidomide mediates degradation
of IKZF1 and IKZF3, both transcription factors expressed in T cells as
well as in CLL cells.40,41 IKZF3 has recently been shown to be mutated
in a small subset of CLL patients, and is over-expressed in the majority
of CLL patients, suggesting a role in CLL pathogenesis.5 IKZF3
disrupts apoptosis, possibly through promoting upregulation of bcl-2
family proteins.42 Further investigation of lenalidomide and other
cereblon-modulating agents is warranted given these novel findings.

The mechanism accounting for clinical benefit of lenalidomide
consolidation therapy in our study is unknown. However, the findings
are consistent with positive data from lenalidomide maintenance trials
in CLL35,36 and lymphoma37 despite lack of deepening response.

The relevance of this study’s findings in the context of a rapidly
moving field of CLL therapeutics must be considered and outside of
the lenalidomide consolidation arm are of little impact. High-sensitivity
flow cytometry and IGHV mutational analysis was not an integral

with del(11q) was lower than that observed in non-del(11q)
patients. Because this trial required $20% of cells with loss of 1
copy to categorize as del(11q), which is a higher threshold than
what is typically used in practice, the discrepant results could be
due to enrichment of more aggressive cases.

24 JULY 2018 x VOLUME 2, NUMBER 14

LENALIDOMIDE CONSOLIDATION IMPROVES OUTCOME IN CLL

1715

biomarker and was not performed as part of the trial nor was minimal
residual disease assessment. Recent observations have suggested
that for the small subset of young CLL patients with IGHV-mutated
CLL, treatment with FCR may promote prolonged durable remissions
and cure.13 Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib43,44
are being increasingly used as initial therapy for CLL treatment.
In addition to inhibiting BTK, ibrutinib also inhibits interleukin2–inducible kinase, which favorably modulates the immune
system.45,46 Thus, combining ibrutinib with lenalidomide might
provide dual modulation of the immune system through different
mechanisms. Several studies are ongoing with this combination
treatment. If effective, such approaches might offer potential benefits
such as allowing discontinuation of ibrutinib or alternatively preventing relapse of high-risk CLL patients such as those with complex
karyotype.47,48 The data from our study justify continued study of
lenalidomide or related compounds in the treatment of CLL.
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